AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Outlook on Asia-Pacific’s $207.8 Million Human Microbiome Market 2019-2025 - ResearchAndMarkets.com

May 20, 2019

DUBLIN--(BUSINESS WIRE)--May 20, 2019--

The “Asia Pacific Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product, Disease, Application, and Country” report has been added to ResearchAndMarkets.com’s offering.

The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017. The market is estimated to grow with a CAGR of 22.8% from 2018-2025.

The growth of the market is driven by the factors such as rising chronic disease due to change in lifestyle and growing interest in human microbiome treatment approach. Whereas, stringent regulatory environment and lack of awareness about human microbiome science is likely to have a negative impact on the growth of the market in the coming years.

Probiotics, prebiotics dietary supplements and foods that contain live microbes have been studied thoroughly to assess their effects on human health. The Gut Health Congress was held in Hong Kong Asia in 2018, the conference explore in detail of diet & personalised nutrition, gastrointestinal microbiome and several case studies with regards to clinical studies, diagnostics studies, treatment methods, biomarker developments, molecular therapy and gastrointestinal diseases.

Also, the 5th Microbiome R&D and Business Collaboration Congress was held in Taiwan, Asia in March 2019, the conference focused on recent developments in gut microbiome, skin microbiome, infant, women and oral health, therapeutics, microbiome and diet.

Also, many companies are designing and developing many microbiome therapies. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.

Japan is anticipated to lead the adoptions of Human microbiome across the Asia Pacific region through the forecast period. Researchers from Japan are using the outcomes of studies on centenarians in the country to try and produce new products that will replicate the beneficial aspects of their microbiota.

The goal of the collaboration is to solve few of the major technological hurdles in advancing stem cell research. Moreover, Cykinso (Tokyo) received the US$ 2.3 million (270 million yen) funds from the Regional Health Care Industry Support Fund, develop and sell Mykinso or a test kit for intestinal flora. The company plans to use the funds for business development purposes, which include using the data collected from the intestinal flora tests to develop a system for offering nutritional guidance. Thus, the investments and the initiatives taken by the government are likely to propel the growth of the market in the forecast period.

Key Topics Covered

Part 1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

Part 2. Asia Pacific Human Microbiome Market - Key Takeaways

Part 3. Asia Pacific Human Microbiome Market - Market Landscape

3.1 Overview

3.2 Market Segmentation

3.3 Pest Analysis

Part 4. Asia Pacific Human Microbiome Market - Key Market Dynamics

4.1 Key Market Drivers

4.1.1 Rising Chronic Disease Due To Change In Lifestyle

4.1.2 Growing Interest In Human Microbiome Treatment Approach

4.2 Key Market Restraints

4.2.1 Stringent Regulatory Environment

4.2.2 Lack of Awareness About Human Microbiome Science

4.3 Key Market Opportunities

4.3.1 Growing Initiatives To Raise the Awareness In Emerging Nations

4.4 Future Trends

4.4.1 the Human Microbiome Drug Development Is Revolutionizing the Medical Industry

4.5 Impact Analysis

Part 5. Human Microbiome Market - Asia Pacific Analysis

5.1 Asia Pacific Human Microbiome Market Revenue Forecasts and Analysis

5.2 Market Positioning

5.3 Performance of Key Players

- Enterome

- Yakult Honsha Co. Ltd.

5.4 Expert Opinions

Part 6. Asia Pacific Human Microbiome Market Analysis - by Product

6.1 Overview

6.2 Asia Pacific Human Microbiome Market, by Product, 2017 & 2025 (%)

6.3 Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025, by Product (US$ Mn)

6.4 Foods Market

6.5 Medical Food Market

6.6 Probiotics Market

6.8 Drugs Market

6.9 Diagnostic Devices Market

6.10 Supplements Market

Part 7. Asia Pacific Human Microbiome Market Analysis - by Disease

7.1 Overview

7.2 Asia Pacific Human Microbiome Market, by Disease, 2017 & 2025 (%)

7.3 Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025, by Disease (US$ Mn)

7.4 Diabetes Market

7.5 Cancer Market

7.6 Autoimmune Disorders Market

7.7 Obesity Market

7.8 Mental Disorders Market

7.9 Others Market

Part 8. Asia Pacific Human Microbiome Market Analysis - by Application

8.1 Overview

8.2 Asia Pacific Human Microbiome Market, by Application, 2017 & 2025 (%)

8.3 Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025, by Application (US$ Mn)

8.4 Diagnostics Market

8.5 Therapeutics Market

Part 9. Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025

9.1 Overview

9.2 Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025 (US$ Mn)

9.3 Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025, by Product (US$ Mn)

9.4 Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025, by Disease (US$ Mn)

9.5 Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025, by Application (US$ Mn)

9.6 Asia Pacific Human Microbiome Market Revenue and Forecasts To 2025, by Country (%)

9.7 China Human Microbiome Market Revenue and Forecasts To 2025 (US$ Mn)

9.8 Japan Human Microbiome Market Revenue and Forecasts To 2025 (US$ Mn)

9.9 India Human Microbiome Market Revenue and Forecasts To 2025 (US$ Mn)

Part 10. Human Microbiome Market - Industry Landscape

10.1 Overview

10.2 Growth Strategies In the Human Microbiome Market, 2015-2018

10.3 Organic Growth Strategies

10.3.1 Overview

10.3.2 Product Launch & Approvals

10.3.3 Expansion

10.3.4 Patent and License

10.4 Inorganic Growth Strategies

10.4.1 Overview

10.4.2 Acquisitions

10.4.3 Partnerships, Collaborations & Agreements

10.4.4 Joint Ventures

Part 11. Human Microbiome Market-Key Company Profiles

  • Enterome
  • MicroBiome Therapeutics LLC
  • Rebiotix Inc.
  • Yakult Honsha Co. Ltd.
  • Osel Inc.
  • Vedanta Biosciences Inc.
  • Metabiomics Corporate
  • Synthetic Biologics Inc.
  • DuPont
  • BiomX Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/euinhn

View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005308/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biopharmaceuticals

KEYWORD: ASIA PACIFIC

INDUSTRY KEYWORD: HEALTH GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/20/2019 05:27 AM/DISC: 05/20/2019 05:27 AM

http://www.businesswire.com/news/home/20190520005308/en

All contents © copyright 2019 The Associated Press.All rights reserved.